News

DENVER, Colo. — Adding the angiogenesis inhibitor bevacizumab to standard treatment for malignant pleural mesothelioma (MPM) increases life expectancy without severe toxicity, according to research presented today at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC). The French multicenter randomized phase 3 trial data was presented by Dr. Arnaud Scherpereel, Head of the Pulmonary and Thoracic Oncology Department and Professor at the University Hospital (CHU) of Lille, France.

DENVER, Colo. — Two Phase III studies with anamorelin found that the medication effectively combats wasting and increases body weight and lean body mass in certain lung cancer patients. Results from the ROMANA 1 and ROMANA 2 Phase III trial of anamorelin were presented today in Denver, Colo. at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC).

DENVER, Colo. — Every hour lost to the cancer drug regulatory process costs 29 life-years lost in the U.S. and 260 life-years worldwide, according to research presented today at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC). Dr. David Stewart, Head, Division of Medical Oncology, University of Ottawa/The Ottawa Hospital, presented data on how the regulatory process of new therapies slows progress by increasing drug developments costs and by producing speed bumps that delay approval of useful drugs. This process also increases resources required to document that other agents are ineffective.

DENVER, Colo. — The International Association for the Study of Lung Cancer (IASLC) today issued a new statement on Tobacco Control and Smoking Cessation at the 16th World Conference on Lung Cancer (WCLC) in Denver. The statement calls for higher taxes on tobacco products, comprehensive advertising and promotion bans of all tobacco products and product regulation including pack warnings.

DENVER, Colo. (Monday, September 7, 2015) — Groundbreaking research presented today by international leaders in lung cancer highlighted the benefits of focusing on the prevention of lung cancer, of spreading the message about the dangers of tobacco and of improving our regulatory process so unnecessary lives aren’t lost. Encouraging data about therapies to combat wasting and increase life expectancy were also shared at the at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer (IASLC), which also released a new statement on Tobacco Control and Smoking Cessation.

The International Association for the Study of Lung Cancer (IASLC) will hold a press conference on Tuesday, Sept. 8, 2015 at 9:45 a.m. MDT to reveal findings from key abstracts detailing advances in lung cancer study and research. Full presentations of these abstracts and other lung cancer study advancements will take place throughout the 16th World Conference on Lung Cancer (WCLC).

Pages